Akebia Ther (AKBA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $131.67M
Last updated: Nov 17, 2026 at 4:38 PM ET
Akebia Ther (AKBA) Stock Chart
Akebia Ther (AKBA) has a latest price of $0.40 on Nov 17, 2026, 76.9% below its 52-week high of $1.73. Its price fell 76.0% over the past 12 months. The month-end price fell 90.6% over the 10 years through Oct 2026, a compound annual decline of 21.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $19.67 in Sep 2017 and its lowest $0.25 in Oct 2022, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart AKBA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for AKBA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 54.8%, and over 6 months it fell 55.3%. The month-end price fell 19.7% over the 3 years through Oct 2026, a compound annual decline of 7.1%.
| Period | Change |
|---|---|
| 1 month | -41.1% |
| 3 months | -54.8% |
| 6 months | -55.3% |
| 12 months | -76.0% |
| 12 months, with dividends | -76.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -19.7% | -7.1% |
| 5 years | -75.4% | -24.4% |
| 10 years | -90.6% | -21.1% |
Price by Year
Its best calendar year was 2023, when the price rose 114.9%, and its weakest was 2022, when it fell 74.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.71 | -56.1% |
| 2025 | $1.61 | -15.3% |
| 2024 | $1.90 | +53.2% |
| 2023 | $1.24 | +114.9% |
| 2022 | $0.58 | -74.5% |
| 2021 | $2.26 | -19.3% |
| 2020 | $2.80 | -55.7% |
| 2019 | $6.32 | +14.3% |
| 2018 | $5.53 | -62.8% |
| 2017 | $14.87 | +42.8% |
Trading Range
The price is 46.5% below its 50-day average of $0.75 and 63.4% below its 200-day average of $1.09.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.40 | |
| 52-week high | $1.73 | -76.9% |
| 52-week low | $0.36 | +10.9% |
| 50-day average | $0.75 | -46.5% |
| 200-day average | $1.09 | -63.4% |
Price Risk
Over 3 years, its largest fall from a peak was 90.0%.
| Measure | Value |
|---|---|
| 1-year beta | 2.78 |
| Largest fall, 1 year | -77.3% |
| Largest fall, 3 years | -90.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About AKBA
What is AKBA's 1-year price change?
Akebia Ther's price fell 76.0% over the past 12 months. With dividends included, the 12-month total return was -76.0%.
What is AKBA's 5-year price change?
Akebia Ther's month-end price fell 75.4% over the 5 years through Oct 2026, a compound annual decline of 24.4%. These figures leave out dividends.
What is AKBA's 52-week high and low?
Akebia Ther's 52-week high is $1.73 and its 52-week low is $0.36. Its latest price of $0.40 on Nov 17, 2026 is 76.9% below the high.
What is AKBA's beta?
Akebia Ther's 1-year beta against the S&P 500 is 2.78, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 77.3%.
Is the AKBA chart free?
Yes. Advanced Charting for AKBA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
AKBA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors